Earnings Feed
Start Free
|4Feb 3, 7:16 PM ET

Hooks Corwin Dale 4

Research Summary

AI-generated summary

Updated

Applied Therapeutics (APLT) CCO Hooks Receives RSUs, Disposes Shares

What Happened

  • Hooks Corwin Dale, Chief Commercial Officer of Applied Therapeutics (APLT), was granted 312,500 compensatory Restricted Stock Units (RSUs) on 2025-12-19 (reported on Form 4 filed 2026-02-03). Those RSUs vested and were converted as part of a change in control/merger.
  • The filing also reports dispositions totaling 868,253 shares (5,753 shares described as a change-of-control disposition and 862,500 shares disposed to the issuer). Under the Merger Agreement each cancelled share was converted into $0.088 cash per share plus one non-tradeable contingent value right (CVR). The cash equivalent of the disposed shares is approximately $76,406.26.

Key Details

  • Transaction dates and amounts:
    • 2025-12-19: Grant/award (A) — 312,500 RSUs @ $0.00 (compensatory RSUs).
    • 2026-02-03: Disposition in change of control (U) — 5,753 shares (disposed).
    • 2026-02-03: Disposition to issuer (D) — 862,500 shares (disposed).
  • Merger terms (footnotes): Merger effective Jan 28, 2026 — each share (and each RSU, whether vested or unvested) was converted into $0.088 cash per share (net) plus one non-tradeable CVR.
  • Filing: Form 4 filed 2026-02-03 reporting the above transactions with a report period of 2025-12-19.
  • Holdings note: The filing includes an administrative correction adjusting prior-reported total holdings (F2). The Form 4 does not specify remaining common shares held after conversion beyond the merger consideration and CVRs.
  • Codes explained: A = award/grant (RSUs); D/U = dispositions tied to the issuer/change in control. These were not open-market purchases or sales for cash on an exchange.

Context

  • The RSUs were compensatory awards that vested upon the change in control and were then converted under the Merger Agreement — this is a structural transaction tied to the corporate merger, not a typical open-market buy or sell decision by the insider.
  • The cash received per share is small ($0.088/share) and the holder also received non-tradeable contingent value rights (CVRs) as part of the merger consideration.